{"id":"W3016349309","doi":"10.1002/cncr.32883","title":"Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Bavarian Nordic; Sirtex Medical; FibroGen; Eisai; Celgene; Rakuten Medical; Aminex Therapeutics; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; MacroGenics; Celldex Therapeutics; Principia Biopharma; Puma Biotechnology; National Institutes of Health; Regeneron Pharmaceuticals; BioMarin Pharmaceutical; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Alexion Pharmaceuticals; Halozyme; Kyowa Hakko Kirin; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Neuroendocrine tumors; Clinical endpoint; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Oncology; Progressive disease; Immunotherapy; Cancer; Disease; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005702347,0.0003613497,0.0007060462,0.00003634653,0.0002048866,0.00003842985,0.0003476857,0.000006699363,0.00004057714],"category_scores_gemma":[0.001012369,0.0001692795,0.000202075,0.0003954112,0.0002006634,0.00009116217,0.00007745822,0.0002147395,0.000005498484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001755444,"about_ca_system_score_gemma":0.0003536593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001613925,"about_ca_topic_score_gemma":0.0005720506,"domain_scores_codex":[0.9974545,0.0001562936,0.00054875,0.0006837294,0.0005450165,0.0006117492],"domain_scores_gemma":[0.9965478,0.001962349,0.0002307619,0.0007241601,0.0002664076,0.0002685771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.4425594,0.009117593,0.1614041,0.0009167324,0.004940362,0.01862326,0.03048863,0.001533307,0.03443279,0.0001000649,0.008283416,0.2876003],"study_design_scores_gemma":[0.1297245,0.09047844,0.3053923,0.0007081115,0.003939258,0.0005226309,0.01498581,0.003185305,0.337923,0.0001321507,0.1120594,0.0009491202],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9689642,0.003722918,0.00002654073,0.01779776,0.0001361707,0.008420447,0.0007771822,0.00008058982,0.00007416384],"genre_scores_gemma":[0.9929873,0.00161779,0.0001738133,0.0009146942,0.0005566736,0.002821565,0.00005962009,0.00007105044,0.000797449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3128349,"threshold_uncertainty_score":0.6903018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07047732118771373,"score_gpt":0.3677005988134592,"score_spread":0.2972232776257455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}